When compared with classic DMG, H3K27-altered, survival also tends to be longer (median OS of 37 and 36 months in BRAF-altered and FGFR1-altered H3K27M gliomas, versus 12 months of median OS in BRAF- and FGFR1-wildtype H3K27M gliomas). This evidence concerns the gene BRAF and central nervous system cancer.